Scholar Rock Holding Corp (SRRK : NASDAQ)
Common Stock
$51.19
USD
+3.03 (6.29%)
Last updated: 2026-09-22
Get SRRK alerts:
SRRK
Scholar Rock Holding Corp
WealthAwesomePerformance
1 Day
+6.29%
1 Week
+2.38%
1 Month
-9.40%
YTD
+9.03%
Key Statistics
Market Cap
$6.23B
52W High
$61.76
52W Low
$27.07
P/E Ratio
-
50 Day MA
$52.70
200 Day MA
$48.26
Beta
0.68
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/22/2026 | $48.07 | $51.67 | $48.07 | $51.19 | $51.19 | 3,639,136 |
| 9/21/2026 | $47.35 | $49.15 | $46.54 | $48.16 | $48.16 | 2,851,676 |
| 9/18/2026 | $48.02 | $48.52 | $45.88 | $46.65 | $46.65 | 3,252,800 |
| 9/17/2026 | $49.52 | $49.95 | $48.00 | $49.02 | $49.02 | 3,372,092 |
| 9/16/2026 | $50.01 | $50.65 | $48.59 | $49.37 | $49.37 | 3,630,825 |
| 9/15/2026 | $50.77 | $51.11 | $46.54 | $50.00 | $50.00 | 5,251,145 |
| 9/14/2026 | $56.51 | $56.90 | $51.58 | $51.85 | $51.85 | 4,048,433 |
| 9/11/2026 | $55.67 | $56.94 | $54.91 | $55.41 | $55.41 | 994,404 |
| 9/10/2026 | $54.01 | $56.71 | $53.86 | $55.67 | $55.67 | 1,175,600 |
| 9/9/2026 | $57.30 | $57.65 | $54.44 | $54.62 | $54.62 | 1,601,800 |
Analyst Price Targets
Based on 10 analysts covering SRRK · as of Sep 23, 2026
Wall Street analysts forecast SRRK stock price to rise 37.5% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
US$70.38
+37.5% Upside
Previously US$69.94 on Sep 17, 2026
Current Price
US$51.19
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SRRK's historical volatility
30-Day Vol
48.2%
Annualized
90-Day Vol
48.7%
Annualized
Trend (90d)
-28.3%
Annualized drift
90d Mean
US$46.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$49.49 | US$41.91 – US$58.45 |
| 60 trading days | US$47.85 | US$37.83 – US$60.54 |
| 90 trading days | US$46.27 | US$34.69 – US$61.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-404.88M
- Profit Margin
- 0.00%
- ROE (TTM)
- -167.77%
- EPS (Diluted)
- -3.31
- Book Value
- 2.09
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About SRRK.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| LHSW | Lianhe Sowell International Group Ltd Ordinary Shares | $0.89 | +105.33% |
| KFIIR | K&F Growth Acquisition Corp. II Rights | $0.09 | +73.36% |
| ZEO | Zeo Energy Corp. | $0.49 | +57.04% |
| RAIN | Rain Enhancement Technologies Holdco, Inc. Class A Common Stock | $1.02 | +54.31% |
| NBRGR | Newbridge Acquisition Limited Rights | $0.36 | +53.19% |
| GRML | Greenland Mines Ltd | $14.15 | +50.21% |
| CWD | CaliberCos Inc. Class A Common Stock | $0.73 | +40.33% |
| FLNA | Filana Therapeutics, Inc. | $1.03 | +39.28% |
SRRK.US news timeline
1 article covering SRRK.US, most recent first
Latest